Stock CYCLACEL PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Cyclacel Pharmaceuticals Inc Nasdaq

Equities

US23254L3069

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cyclacel Pharmaceuticals Inc
Jun. 26 Sector Update: Health Care Stocks Softer Late Afternoon MT
Jun. 26 Sector Update: Health Care Stocks Lower in Afternoon Trading MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Sector Update: Health Care Stocks Lower in Afternoon Trading
MT
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise
MT
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
CI
Cyclacel Pharmaceuticals : A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma
PU
Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib?s Potential as Precision Medicine for Cancer
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000
MT
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
AQ
Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding
CI
Top Midday Gainers
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting
MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding
CI
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing
DJ
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation
PU
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
CI
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYCC Stock
  4. Stock
  5. News Cyclacel Pharmaceuticals Inc